Clinical Trial Goal
To find out if mezigdomide is safe and works well to treat multiple myeloma that has relapsed or is refractory compared to standard care
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with the following:
- An anti-CD38 monoclonal antibody like daratumumab
- Lenalidomide
- Have not been treated with carfilzomib or mezigdomide. Your doctor can tell you this
- Have not had an autologous (your own cells) blood or marrow transplant (BMT) in the last 3 months
- Have not had an allogeneic (cells from a donor) BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Carfilzomib is a small molecule inhibitor that blocks proteasome function in certain cells.
Dexamethasone is a drug that reduces inflammation.
Mezigdomide is an immunomodulatory drug that doctors think will help fight cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Dexamethasone is a drug that reduces inflammation.
Mezigdomide is an immunomodulatory drug that doctors think will help fight cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
- Group 1 – Carfilzomib and dexamethasone
- Group 2 – Carfilzomib and dexamethasone plus mezigdomide
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
- Carfilzomib – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Dexamethasone - Given as a pill you take by mouth
- Mezigdomide – Group 2 only - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved carfilzomib and dexamethasone for the treatment of multiple myeloma. The FDA has not yet approved mezigdomide.
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
Locations
Sponsors
lead: Bristol-Myers Squibb
